Immunonutrition vs EPA-DHA Enriched Nutritional Support in Patients With Cancer Undergoing Surgery (Immunonutritio)

IMMUNONUTRITION VS EPA-DHA ENRICHED NUTRITIONAL SUPPORT IN PATIENTS WITH CANCER UNDERGOING SURGERY

To compare clinical and molecular effects of nutritional support (immunonutrition or EPA-DHA enriched oral nutritional supplements) in patients with cancer undergoing surgery.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with cancer undergoing surgery (primary tumor location; gastrointestinal tract, ovarian, peritoneal carcinomatosis

Description

Inclusion Criteria:

  • Patients with cancer undergoing surgery (primary tumor location; gastrointestinal tract, ovarian, peritoneal carcinomatosis)

Exclusion Criteria:

  • End-stage liver disease
  • End-stage kidney disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with cancer undergoing surgery (primary tumor location: gastrointestinal tract, ovary)

Patients undergo nutritional prehabilitation before surgery

Patients will receive nutritional advice and 2 oral nutritional supplements with arginine, fatty acids and nucleotides

Patients will receive nutritional advice and 2 oral nutritional supplements enriched with EPA and DHA

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body composition changes
Time Frame: 1-3 months

changes in fat mass, fat-free mass, lean mass and phase angle

1-3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cytokines changes
Time Frame: 1-3 months

Changes in circulating cytokines (IL6, IL8, MIP10)

1-3 months
Metabolites changes
Time Frame: 1-3 months

Changes in circulating metabolites including lipids and muscle-related metabolites

1-3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 2, 2026

Primary Completion (Estimated)

November 2, 2027

Study Completion (Estimated)

November 2, 2028

Study Registration Dates

First Submitted

September 30, 2026

First Submitted That Met QC Criteria

September 30, 2026

First Posted (Actual)

October 6, 2026

Study Record Updates

Last Update Posted (Actual)

October 6, 2026

Last Update Submitted That Met QC Criteria

September 30, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Immunonutrition vs EPA-DHA

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.